Acquisitions, Financial Results, Clinical Trial Applications, and Upcoming Earnings Schedules - Research Report on Illumina,

  Acquisitions, Financial Results, Clinical Trial Applications, and Upcoming
 Earnings Schedules - Research Report on Illumina, DENTSPLY, Alnylam, Sirona,
                                 and Santarus

PR Newswire

NEW YORK, November 1, 2013

NEW YORK, November 1, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Illumina
Inc. (NASDAQ: ILMN), DENTSPLY International Inc. (NASDAQ: XRAY), Alnylam
Pharmaceuticals, Inc. (NASDAQ: ALNY), Sirona Dental Systems Inc. (NASDAQ:
SIRO), and Santarus, Inc. (NASDAQ: SNTS). Today's readers may access these
reports free of charge - including full price targets, industry analysis and
analyst ratings - via the links below.

Illumina Inc. Research Report

On October 28, 2013, Illumina Inc. (Illumina) announced that it has signed a
definitive agreement to acquire NextBio, a leader in clinical and genomic
informatics. The Company stated that this acquisition will allow Illumina to
offer customers enterprise level bioinformatics solutions that accelerate the
discovery of new associations between the human genome and disease, thus,
enabling the application of those discoveries within healthcare. Jay Flatley,
President and CEO of Illumina, commented, "This agreement with NextBio
demonstrates Illumina's unwavering commitment to drive the adoption of
sequencing in new markets and vastly improve the genomic information
workflow." The Company expects the transaction to close by the end of October
2013. The Full Research Report on Illumina Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/3cf2_ILMN]

DENTSPLY International Inc. Research Report

On October 29, 2013, DENTSPLY International Inc. (DENTSPLY) reported its Q3
2013 financial results. Net sales of the Company grew 1.2% YoY to $704.0
million. Net income attributable to the Company came in at $79.9 million or
$0.55 per diluted share in Q3 2013, compared to $53.4 million or $0.37 per
diluted share in Q3 2012. Commenting on the results, DENTSPLY's Chairman and
CEO Bret Wise stated, "DENTSPLY made solid progress in the third quarter,
achieving growth in each major geographic region and in each of our principal
product categories. This growth, combined with strong improvement in adjusted
operating margins and lower interest costs, drove record earnings for the
third quarter. Market conditions are generally consistent with what we had
anticipated earlier in the year, and thus we are maintaining our expectations
for fiscal 2013 adjusted earnings per diluted share in the range of $2.33 to
$2.38." The Full Research Report on DENTSPLY International Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/6b01_XRAY]

Alnylam Pharmaceuticals, Inc. Research Report

On October 29, 2013, Alnylam Pharmaceuticals, Inc. (Alnylam) announced the
filing of its Clinical Trial Application (CTA) with the U.K. Medicines and
Healthcare products Regulatory Agency, to initiate a Phase I clinical trial
with ALN-AT3, a subcutaneously administered RNAi therapeutic targeting
antithrombin (AT) for the treatment of hemophilia, including people with
"inhibitors". Akshay Vaishnaw, M.D., Ph.D., Executive Vice President and Chief
Medical Officer at Alnylam, said, "Hemophilia is characterized by a genetic
deficiency in clotting factors that ultimately leads to inadequate thrombin
generation and a bleeding disorder. ALN-AT3 aims to correct the hemostatic
imbalance in hemophilia by knocking down AT - an endogenous anticoagulant -
thus increasing thrombin generation and improving hemostasis, and reducing
disease burden. We very much look forward to the continued advancement of
ALN-AT3, including the start of our Phase I clinical trial in early 2014 with
data from hemophilia subjects expected by the end of that year." The Full
Research Report on Alnylam Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/5b29_ALNY]

Sirona Dental Systems Inc. Research Report

On October 24, 2013, Sirona Dental Systems Inc. (Sirona) announced the
schedule of its Q4 FY 2013 earnings release. The Company stated that it will
report its financial results on November 22, 2013, before financial markets
open. Sirona stated that its management team will host a conference call at
8:30 a.m. EST that morning. The Company added that a live webcast of the
presentation will be available at its website, which will also be archived for
twelve months at the same location. The Full Research Report on Sirona Dental
Systems Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/08e7_SIRO]

Santarus, Inc. Research Report

On October 28, 2013, Santarus Inc. (Santarus) announced that it will release
its Q3 2013 financial results on November 7, 2013, after market close.
Santarus informed that its management will host a conference call and webcast
at 5:00 p.m. ET (2:00 p.m. PT) to discuss its results and provide a corporate
update. The Company stated that the call can be accessed live via the Investor
Relations section of its website. In addition, a webcast replay of the call
will be available on the website for 14 days. The Full Research Report on
Santarus, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/22f8_SNTS]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Media Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.